|Bid||0.00 x 1400|
|Ask||0.00 x 1000|
|Day's Range||250.00 - 260.52|
|52 Week Range||181.36 - 349.84|
|Beta (5Y Monthly)||1.32|
|PE Ratio (TTM)||29.98|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The broad-based demand and meaningful price increases in the RMS business particularly in North America are expected to have contributed to Charles River's (CRL) top line in Q4.
Charles River's (CRL) latest partnership is expected to bring a potentially curative therapy, RZ-001, to HCC patients.
Charles River's (CRL) new partnership will enable the clinical development of RNA-based anticancer gene therapy in liver cancer patients.